Vol. 1 No. 8 (2021)
Reimbursement Recommendations

Venetoclax (Venclexta)

Published August 20, 2021

Key Messages

  • CADTH recommends that Venclexta in combination with azacitidine should be reimbursed for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, only if certain conditions are met.
  • Venclexta plus azacitidine should only be reimbursed if prescribed by clinicians who have expertise in managing patients with AML and are familiar with the toxicity profile of this regimen, and if the costs of Venclexta and azacitidine are reduced.
  • Venclexta plus azacitidine should only be covered to treat adult patients who are considered ineligible for standard intensive induction chemotherapy and have not been treated with venetoclax or chemotherapy for myelodysplastic syndrome.